Amarin Corp Plc (AMRN)

[everyonesguess]

In any way, the CVD sNDA submission is a major (or historical) event for the drug Vascepa and the company AMRN. But the pps of AMRN stacked way below $20.

For a long time (since 2013 ADCOM), AMRN is treated as a "frost child" by the market. RI results changed that a bit, but didn't overcome that entirely yet. About BP buyout, it should get more interesting followed sNDA submission (next week).

Whether AMRN pps will jump up or pull back with the sDNA submission, it will define the pattern of AMRN pps for 2019.

Another issue to observe is the PDUFA date. Two-month priority will jump the pps; six-month may not have too much power, and ten-month keep the business as usual.

The RX growth will be the volcano underneath the pps ground. But it is a slow process. We have to wait and see for a considerable period (the 25% RRR almost guaranteed a bright future though).